SCHEMBL21597638

SCHEMBL21597638

COC(=O)c1c(NC(=O)C2CC2)sc2c1CCCC2=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.67
MAPT P10636 4/20 0.67
HSD17B10 Q99714 3/20 0.67
ALDH1A1 P00352 9/20 0.53
GAA P10253 1/20 0.53
RAB9A P51151 2/20 0.48
TSHR P16473 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
FLT3 P36888 1/20 0.47
MCL1 Q07820 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
LMNA P02545 1/20 0.45
NPC1 O15118 1/20 0.45
CNR2 P34972 3/20 0.44
CNR1 P21554 1/20 0.44
POLB P06746 1/20 0.44
CHD1L Q86WJ1 1/20 0.44
PARP9 Q8IXQ6 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21597594 0.88 ALDH1A1 (0.61) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL21597756 0.86 FLT3 (0.50) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL21597675 0.85 MAPT (0.48) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL5445103 0.85 FLT3 (0.66) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL21603922 0.81 KDM4E (1.00) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL5445115 0.76 FLT3 (0.58) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL5445106 0.76 FLT3 (0.58) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL5445111 0.76 FLT3 (0.58) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL9722751 0.74 ALDH1A1 (0.45) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL31435555 0.74 ALDH1A1 (0.44) KDM4EMAPTHSD17B10ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 KDM4E 3965/4885MAPT 2356/4885HSD17B10 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.